产品编号:B416
产品描述:Anti-Human BAFF
反应种属:human
实验方法:ELISA, IHC-F, N, WB
标记:
规格:100ug
供应商:leinco
价格(RMB):5325.00
订购:
说明书:
Goat Anti-Human B Cell Activating Factor (BAFF)
Antigen Affinity Purified
(TNFSF13B, TALL-1, BLyS, THANK, zTNF4, BAFF, CD257, TNFSF20, Delta BAFF)
Polyclonal Antibody
Prod. No.: B416
Host: Goat
Pkg. Size: 1 mg, 100 µg
Storage: -20°C to -70°C
Description
Specificity:
Goat Anti-Human B Cell Activating Factor (BAFF) recognizes Human BAFF. This antigen affinity purified polyclonal antibody was purified using a proprietary chromatographic technique that includes covalently immobilizing the antigen proteins or peptides to agarose based beads. This purification method enhances specificity, reduces nonspecific binding of extraneous IgG and provides you with the most reliable reagent available for your early discovery research.
Background:
B-cell activating factor (BAFF) is the tumor necrosis factor ligand superfamily member 13B (TNFLSF13B), also known as B Lymphocyte Stimulator (BLyS) and TNF- and APOL-related leukocyte expressed ligand (TALL-1) and the Dendritic cell-derived TNF-like molecule (CD257 antigen; cluster of differentiation 257).
BAFF is a glycoprotein which undergoes glycosylation at residue 124. It is expressed as transmembrane protein on various cell types including monocytes, dendritic cells and bone marrow stromal cells. The transmembrane form can be cleaved from the membrane, generating a soluble protein fragment. BAFF is the natural ligand of three unusual tumor necrosis factor receptors named BAFF-R, TACI, and BCMA, all of which have differing binding affinities for it. These receptors are expressed mainly on mature B lymphocytes (TACI is also found on a subset of T-cells and BCMA on plasma cells). TACI binds worst since its affinity is higher for a protein similar to BAFF, called A Proliferation Inducing Ligand (APRIL). BCMA displays an intermediate binding phenotype and will work with either BAFF or APRIL to varying degrees. Signaling trough BAFF-R and BCMA stimulates B lymphocytes to undergo proliferation and to counter apoptosis. All these ligands act as heterotrimers (i.e. three of the same molecule) interacting with heterotrimeric receptors.
BAFF provides critical survival signals to a subset of B cells with intermediate maturation status (T2 B cells) during the immune response. BAFF also plays an important role in the development of lymphoid tissue and enhances the survival of activated memory B cells. Human and mouse BAFF share 86% aa sequence identity.
Known Species Cross Reactivity: Hu+
Immunogen
Purified Recombinant Human BAFF (>98%)
Formulation
This antigen affinity purified polyclonal antibody has been 0.2 µm filtered and lyophilized from modified Dulbecco’s phosphate buffered saline (1X PBS) pH 7.2 – 7.3 containing 5.0% w/v trehalose with no calcium, magnesium, or preservatives present.
Reconstitution
We suggest aseptically reconstituting this lyophilized, antigen affinity purified polyclonal antibody with 1 µl of sterile 1X PBS pH 7.2-7.3. This will result in a final antibody concentration of 0.1 mg/ml.
Endotoxin
<0.6 EU/mg as determined by the LAL method
Storage and Stability
The lyophilized antigen affinity purified polyclonal antibody can be stored desiccated at -20°C to -70°C for twelve months from date of receipt. The reconstituted antibody can be stored for at least four weeks at 2-8°C. For long-term storage of the reconstituted antibody, aseptically aliquot into working volumes and store at -20°C to -70°C in a manual defrost freezer. Avoid Repeated Freeze Thaw Cycles. No detectable loss of activity was observed after six months.
Reported Applications
Indirect ELISA, IHC (NBF/Par.), N, WB
Indirect ELISA: This antibody can be used in an indirect detection ELISA at 0.5 - 1.0 µg/ml with a suitable second step reagent such as Donkey Anti-Goat IgG (H&L)-Horseradish Peroxidase (Leinco Prod. No.: G505). The detection sensitivity of this indirect ELISA for Human BAFF is approximately 0.13 ng/well.
IHC (NBF/Par.): This antibody should give satisfactory staining results when used at a concentration of 15 µg/ml. The recommended secondary antibody for IHC is Donkey Anti-Goat IgG (H&L)-Horseradish Peroxidase (Leinco Prod. No.: G505). For chromogenic detection with high signal and low background use 3, 3'-Diaminobenzidine Tetrahydrochloride (DAB) Substrate Kit (Leinco Prod. No.: D100) or Optional Metal Enhanced DAB Substrate Kit (Leinco Prod. No.: K107).
Neutralization: This antibody is useful for neutralization of Human BAFF bioactivity. The antibody dose required to neutralize 50% (ND50) of the biological activity of Human BAFF (at 5 ng/ml) is 3 - 12 µg/ml.
Western Blotting: To detect Human BAFF this polyclonal antibody can be used at a concentration of 0.1 - 0.2 µg/ml. This polyclonal antibody should be used in conjunction with compatible second-step reagents such as Donkey Anti-Goat IgG (H&L)-Horseradish Peroxidase (Leinco Prod. No.: G505) and a chromogenic substrate such as TMB HRPO Membrane/IHC Substrate UltraSensitive™ One Component "Ready Use" (Leinco Prod. No.: T343). The detection limit for Human BAFF is 5 ng/lane under either reducing or non-reducing conditions. The sensitivity of detection may increase up to 50 fold when a chemiluminescent substrate is used. A suitable Western blotting control is Recombinant Human BAFF (Leinco Prod. No.: B115).
Related Products
Donkey Anti-Goat IgG (H&L)-Horseradish Peroxidase (Leinco Prod. No.: G505)
3, 3'-Diaminobenzidine Tetrahydrochloride (DAB) Substrate Kit (Leinco Prod. No.: D100)
Optional Metal Enhanced DAB Substrate Kit (Leinco Prod. No.: K107)
TMB HRPO Membrane/IHC Substrate UltraSensitive™ One Component "Ready Use" (Leinco Prod. No.: T343)
Recombinant Human BAFF (Leinco Prod. No.: B115)
BAFF (CT) Blocking Peptide (Leinco Prod. No.: B368)
Anti-Human BAFF (Leinco Prod. No.: B379)
Anti-Human BAFF (CT) (Leinco Prod. No.: B359)
Anti-Human BAFF-R (CT) (Leinco Prod. No.: B514)
Anti-Human BAFF (Leinco Prod. No.: B570)
Anti-Human BAFF-Biotin (Antigen Aff. Pur.) (Leinco Prod. No.: B417)
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
